Miglitol: Difference between revisions
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheM |
||
| Line 1: | Line 1: | ||
{{Unreferenced|date=October 2006}} |
{{Unreferenced|date=October 2006}} |
||
{{Drugbox |
{{Drugbox |
||
| ⚫ | |||
| Watchedfields = changed |
|||
| ⚫ | |||
| IUPAC_name = (2''R'',3''R'',4''R'',5''S'')-1-(2-hydroxyethyl)-2-(hydroxymethyl)<br>piperidine-3,4,5-triol |
| IUPAC_name = (2''R'',3''R'',4''R'',5''S'')-1-(2-hydroxyethyl)-2-(hydroxymethyl)<br>piperidine-3,4,5-triol |
||
| image = Miglitol structure.svg |
| image = Miglitol structure.svg |
||
| Line 35: | Line 34: | ||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = 441314 |
| PubChem = 441314 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
| DrugBank = APRD01117 |
| DrugBank = APRD01117 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| Line 40: | Line 40: | ||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 0V5436JAQW |
| UNII = 0V5436JAQW |
||
| KEGG_Ref = {{keggcite|correct|kegg}} |
|||
| KEGG = D00625 |
| KEGG = D00625 |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
Revision as of 06:57, 31 August 2011
 |
 | |
| Clinical data | |
|---|---|
| Trade names | Glyset |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601079 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Dose-dependent |
| Protein binding | Negligible (<4.0%) |
| Metabolism | Nil |
| Elimination half-life | 2 hours |
| Excretion | Renal (95%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.069.670 |
| Chemical and physical data | |
| Formula | C8H17NO5 |
| Molar mass | 207.224 g/mol g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.458 g/cm3 |
| Melting point | 114 °C (237 °F) |
| |
| |
| (verify) | |
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
See also
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |